QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
QQQ   444.17 (-0.15%)
AAPL   171.46 (-1.07%)
MSFT   420.29 (-0.27%)
META   488.07 (-1.17%)
GOOGL   150.83 (-0.03%)
AMZN   180.47 (+0.36%)
TSLA   176.87 (-1.65%)
NVDA   905.13 (+0.29%)
NIO   4.54 (-2.78%)
AMD   180.63 (+0.58%)
BABA   72.50 (+1.27%)
T   17.68 (+0.74%)
F   13.24 (+1.38%)
MU   117.73 (-1.18%)
CGC   9.12 (-4.50%)
GE   174.95 (-2.87%)
DIS   122.77 (+1.48%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.23 (+0.99%)
XOM   116.12 (+1.00%)
NASDAQ:CELU

Celularity (CELU) Stock Price, News & Analysis

$5.12
+0.18 (+3.64%)
(As of 01:58 PM ET)
Today's Range
$4.90
$5.20
50-Day Range
$2.81
$6.96
52-Week Range
$1.59
$8.90
Volume
36,861 shs
Average Volume
275,413 shs
Market Capitalization
$99.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Celularity MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of Celularity in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$5.35 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.85 out of 5 stars

Medical Sector

723rd out of 939 stocks

Pharmaceutical Preparations Industry

332nd out of 433 stocks

CELU stock logo

About Celularity Stock (NASDAQ:CELU)

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

CELU Stock Price History

CELU Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
CELU Apr 2024 10.000 call
CELU Mar 2024 7.500 put
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Celularity Inc. Class A
Stocks to Watch: Intuitive Machines, Celularity
Celularity Announce 1-for-10 Reverse Stock Split
Celularity to Effect 1-for-10 Reverse Stock Split
Celularity Announces 1-for-10 Reverse Stock Split
Celularity Releases CEO Letter to Shareholders
See More Headlines
Receive CELU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/02/2024
Today
3/28/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CELU
Fax
N/A
Employees
225
Year Founded
N/A

Profitability

Net Income
$14.19 million
Net Margins
-1,226.72%
Pretax Margin
-1,226.64%

Debt

Sales & Book Value

Annual Sales
$17.98 million
Cash Flow
$1.82 per share
Book Value
$13.36 per share

Miscellaneous

Free Float
15,367,000
Market Cap
$96.90 million
Optionable
Optionable
Beta
0.24
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Robert Joseph Hariri M.D. (Age 65)
    Ph.D., Founder, CEO & Chairman
    Comp: $1.24M
  • Mr. David C. Beers C.F.A. (Age 54)
    Chief Financial Officer
    Comp: $455.02k
  • Mr. John R. Haines (Age 66)
    Senior EVP, Global Manager & Chief Administrative Officer
    Comp: $503.56k
  • Ramji Krishnan
    Chief Technology Officer
  • Carlos Ramirez
    SVP of Investor Relations
  • Mr. Kyle Harold Fletcher Esq. (Age 39)
    Executive VP, General Counsel & Chief Compliance Officer
  • Dr. Stephen A. Brigido D.P.M. (Age 48)
    President of Degenerative Diseases
  • Dr. Adrian Kilcoyne M.B.A. (Age 53)
    M.D., M.P.H., Executive VP, Chief Medical Officer and Head of Global Affairs, Patient Safety & Patient Affairs
  • Sharmila Koppisetti M.D.
    Senior Vice President of Clinical Dev. Immunology & Drug Safety
  • Mr. Tim Wilk
    Senior Vice President of Technical Operations

CELU Stock Analysis - Frequently Asked Questions

How have CELU shares performed in 2024?

Celularity's stock was trading at $2.4740 on January 1st, 2024. Since then, CELU stock has increased by 102.1% and is now trading at $5.00.
View the best growth stocks for 2024 here
.

Are investors shorting Celularity?

Celularity saw a decline in short interest in March. As of March 15th, there was short interest totaling 388,300 shares, a decline of 16.8% from the February 29th total of 466,600 shares. Based on an average daily volume of 269,900 shares, the short-interest ratio is currently 1.4 days. Approximately 3.7% of the company's shares are short sold.
View Celularity's Short Interest
.

When is Celularity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our CELU earnings forecast
.

How were Celularity's earnings last quarter?

Celularity Inc. (NASDAQ:CELU) released its quarterly earnings results on Tuesday, January, 2nd. The company reported ($0.60) EPS for the quarter. The company earned $3.79 million during the quarter. Celularity had a negative net margin of 1,226.72% and a positive trailing twelve-month return on equity of 30.79%.

When did Celularity's stock split?

Shares of Celularity reverse split on the morning of Thursday, February 29th 2024. The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Celularity's major shareholders?

Celularity's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (19.26%) and Vanguard Group Inc. (1.93%). Insiders that own company stock include Kok Thay Lim and Robert J Hariri.
View institutional ownership trends
.

How do I buy shares of Celularity?

Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CELU) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners